These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 34524406)

  • 1. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
    Maruani A; Tavernier E; Boccara O; Mazereeuw-Hautier J; Leducq S; Bessis D; Guibaud L; Vabres P; Carmignac V; Mallet S; Barbarot S; Chiaverini C; Droitcourt C; Bursztejn AC; Lengellé C; Woillard JB; Herbreteau D; Le Touze A; Joly A; Léauté-Labrèze C; Powell J; Bourgoin H; Gissot V; Giraudeau B; Morel B
    JAMA Dermatol; 2021 Nov; 157(11):1289-1298. PubMed ID: 34524406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
    Maruani A; Boccara O; Bessis D; Guibaud L; Vabres P; Mazereeuw-Hautier J; Barbarot S; Chiaverini C; Blaise S; Droitcourt C; Mallet S; Martin L; Lorette G; Woillard JB; Jonville-Bera AP; Rollin J; Gruel Y; Herbreteau D; Goga D; le Touze A; Leducq S; Gissot V; Morel B; Tavernier E; Giraudeau B;
    Trials; 2018 Jun; 19(1):340. PubMed ID: 29945674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.
    Leducq S; Caille A; Barbarot S; Bénéton N; Bessis D; Boccara O; Bursztejn AC; Chiaverini C; Dompmartin A; Droitcourt C; Gissot V; Goga D; Guibaud L; Herbreteau D; Le Touze A; Léauté-Labrèze C; Lorette G; Mallet S; Martin L; Mazereeuw-Hautier J; Phan A; Plantin P; Quéré I; Vabres P; Bourgoin H; Giraudeau B; Maruani A;
    Trials; 2019 Dec; 20(1):739. PubMed ID: 31847908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial.
    Marchand A; Caille A; Gissot V; Giraudeau B; Lengelle C; Bourgoin H; Largeau B; Leducq S; Maruani A
    Trials; 2022 Jul; 23(1):557. PubMed ID: 35804404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series.
    Le Sage S; David M; Dubois J; Powell J; McCuaig CC; Théorêt Y; Kleiber N
    Pediatr Dermatol; 2018 Jul; 35(4):472-477. PubMed ID: 29790593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of sirolimus in children with lymphatic malformations of the head and neck.
    Wiegand S; Dietz A; Wichmann G
    Eur Arch Otorhinolaryngol; 2022 Aug; 279(8):3801-3810. PubMed ID: 35526176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective multicenter study of sirolimus for complicated vascular anomalies.
    Ji Y; Chen S; Yang K; Zhou J; Zhang X; Jiang X; Xu X; Lu G; Qiu L; Kong F; Zhang Y
    J Vasc Surg; 2021 Nov; 74(5):1673-1681.e3. PubMed ID: 34082006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral rapamycin: an alternative in children with complicated vascular abnormalities.
    Gómez Sánchez A; Redondo Sedano JV; Pérez Alonso V; Martí Carrera ME; Baro Fernández M; Palencia Pérez SI; Gallego Herrero MC; Gómez Fraile A; Delgado Muñoz MD
    Cir Pediatr; 2020 Oct; 33(4):183-187. PubMed ID: 33016658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.
    Ozeki M; Nozawa A; Yasue S; Endo S; Asada R; Hashimoto H; Fukao T
    Orphanet J Rare Dis; 2019 Jun; 14(1):141. PubMed ID: 31196128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.
    Hammer J; Seront E; Duez S; Dupont S; Van Damme A; Schmitz S; Hoyoux C; Chopinet C; Clapuyt P; Hammer F; Vikkula M; Boon LM
    Orphanet J Rare Dis; 2018 Oct; 13(1):191. PubMed ID: 30373605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus treatment for paediatric head and neck lymphatic malformations: a systematic review.
    Saibene AM; Rosso C; Felisati G; Pignataro L; Schindler A; Ghilardi G; Colletti G; Gaffuri M; Mozzanica F
    Eur Arch Otorhinolaryngol; 2023 Aug; 280(8):3529-3540. PubMed ID: 37115326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Sirolimus: An Option in the Management of Neonates with Life-Threatening Upper Airway Lymphatic Malformations.
    Triana P; Miguel M; Díaz M; Cabrera M; López Gutiérrez JC
    Lymphat Res Biol; 2019 Oct; 17(5):504-511. PubMed ID: 30985248
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe adverse events during sirolimus "off-label" therapy for vascular anomalies.
    Rössler J; Baselga E; Davila V; Celis V; Diociaiuti A; El Hachem M; Mestre S; Haeberli D; Prokop A; Hanke C; Loichinger W; Quéré I; Baumgartner I; Niemeyer CM; Kapp FG
    Pediatr Blood Cancer; 2021 Aug; 68(8):e28936. PubMed ID: 33580918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with Congenital Low-Flow Vascular Malformation Treated with Low Dose Sirolimus.
    Harbers VEM; Rongen GAPJM; van der Vleuten CJM; Verhoeven BH; de Laat PCJ; van der Horst CMAM; Klein WM; Schultze Kool LJ; Loo DMWMT
    Adv Ther; 2021 Jun; 38(6):3465-3482. PubMed ID: 34003452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of superficial vascular anomalies with topical sirolimus: A multicenter case series.
    Dodds M; Tollefson M; Castelo-Soccio L; Garzon MC; Hogeling M; Hook K; Boull C; Maguiness S
    Pediatr Dermatol; 2020 Mar; 37(2):272-277. PubMed ID: 31957126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Sirolimus for Treatment of Orbital Lymphatic Malformations: A Systematic Review.
    Shoji MK; Shishido S; Freitag SK
    Ophthalmic Plast Reconstr Surg; 2020; 36(3):215-221. PubMed ID: 31990892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review.
    Wiegand S; Wichmann G; Dietz A
    Lymphat Res Biol; 2018 Aug; 16(4):330-339. PubMed ID: 29924669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sirolimus on coagulopathy of slow-flow vascular malformations.
    Mack JM; Verkamp B; Richter GT; Nicholas R; Stewart K; Crary SE
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27896. PubMed ID: 31250546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus.
    Durand R; Reid JR; Belasco JB; Shellikeri S; Calle-Toro JS; Cahill AM; Srinivasan A
    AJR Am J Roentgenol; 2021 Sep; 217(3):741-752. PubMed ID: 33405944
    [No Abstract]   [Full Text] [Related]  

  • 20. Topical sirolimus for the treatment of cutaneous manifestations of vascular anomalies: A case series.
    Badia P; Ricci K; Gurria JP; Dasgupta R; Patel M; Hammill A
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28088. PubMed ID: 31930696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.